ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Files An 8-K Other Events
Item 8.01 Other Events.
announced new preclinical data with VB4-845, the active
pharmaceutical ingredient used to formulate
ViciniumTM>and ProxiniumTM, and
deBouganin, the de-immunized payload used in the Companys
systemically-administered drug candidates. These data were
presented at the American Association of Cancer Research (AACR)
Annual Meeting 2017 in Washington, D.C. A copy of this press
release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit
No.
|
Document
|
|
|
99.1
|
Press release of Eleven Biotherapeutics, Inc., dated
April 2, 2017. |
|
About ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO)
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF). ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Recent Trading Information
ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) closed its last trading session 00.00 at 2.20 with 313,262 shares trading hands.
